http://7thspace.com/headlines/379784/california_gang_members_associates_hotel_indicted_on_prostitution_related_racketeering_charges.html
SAN DIEGO, CA—United States Attorney Laura E Duffy announced today the unsealing of an indictment charging 38 individuals and one Limited Liability Company (LLC) with conspiracy to conduct enterprise affairs through a pattern of racketeering activity (RICO). Specifically, the defendants are charged with using a corrupt enterprise to conduct a pattern of racketeering activity, namely, prostitution of minors and adults, use of facilities of interstate commerce to promote prostitution, drug trafficking, and other gang-related crimes. The charged racketeering activity stems from an extensive, 18 month, multi-agency gang investigation entitled Operation Vice Grip in Oceanside, California and surrounding North County areas. In addition to the criminal charges, the indictment also alleges the criminal forfeiture of the Oceanside Travelodge hotel.
According to the indictment, the defendants are charged as members, associates, and facilitators of the Oceanside Crip enterprise (“Oceanside Crips”) composed of various Crip gang “sets,” including the “Insane Crip Gang,” “Deep Valley Crips” and “Crook, Mob, Gangsters.” All three Crip sets are based primarily in Oceanside, and over the last several years have cooperated and interacted to the point that traditional gang distinctions between them have broken down. Specifically, the indictment alleges that since 2005, members of the Oceanside Crip Enterprise engaged in multiple racketeering acts in furtherance of the enterprise, including, among other things, the sex trafficking of minors and adults; attempted murder; kidnapping; extortion; and the distribution of controlled substances. The enterprise members also worked together to protect, promote, and expand their territory against rival gangs. The indictment alleges that senior members of the Oceanside Crips enterprise controlled and directed the activities of more junior members, even from prison.
The indictment further alleges that defendants identified as “pimps” (a person who befriends, recruits, trains, and/or panders a person for prostitution) and “bottoms” (a pimp’s most trusted/senior prostitute) promoted and managed prostitution activities in San Diego County, California, and elsewhere. As set out in the indictment, the Oceanside Crips enterprise has, in recent years, increasingly focused its for-profit criminal activity on pimping and prostituting adult and juvenile females in Oceanside, California, and elsewhere within northern San Diego County and throughout the United States. To this end, as described in the indictment, gang-controlled prostitution spawned a “pimping” subculture, known as “The Game,” which operates under a set of strictly observed rules, with consequences for individuals who violate them—including, but not limited to, physical abuse and/or public humiliation. As alleged in the indictment, the majority of the defendants named in the indictment collaborated with one another as members, associates, and facilitators of the enterprise to carry out prostitution activities, primarily in and around low-cost motels in North County, including the Oceanside Travelodge.
As detailed in the indictment, Oceanside Crips Enterprise members and associates also worked together to recruit new prostitutes. Recruitment efforts generally focused on vulnerable juvenile females who were runaways or from broken homes. Furthermore, as detailed in the indictment, Enterprise “pimps” and “bottoms” conducted extensive online recruitment via various social networking websites, including MySpace, Facebook, and Twitter. As alleged, upon recruiting prostitutes, enterprise “pimps” routinely provided them with controlled substances and alcohol in order to manipulate their loyalty and increase productivity as related to prostitution.
Monday, May 2, 2011
Harris James Associates Biomedicine News: Can Hobbyists and Hackers Transform Biotechnology?
http://www.openpr.com/news/172549/Harris-James-Associates-Biomedicine-News-Can-Hobbyists-and-Hackers-Transform-Biotechnology.html
(openPR) - James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter.
(openPR) - James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter.
For most of us, managing our health means visiting a doctor. The more serious our concerns, the more specialized a medical expert we seek. Our bodies often feel like foreign and frightening lands, and we are happy to let someone with an MD serve as our tour guide. For most of us, our own DNA never makes it onto our personal reading list.
Harris James Associates Update: Congressional forum on biotech jobs focuses on FDA By Keith Darcé
http://www.onlineprnews.com/news/131306-1303817804-harris-james-associates-update-congressional-forum-on-biotech-jobs-focuses-on-fda-by-keith-darc.html
Online PR News – 28-April-2011 –Harris James Associates Update: Overly cautious government regulators, threats to basic science research funding and burdensome taxes are holding back job creation by drug and medical device companies and slowing the delivery of innovative new therapies to patients, biotechnology industry experts told federal lawmakers Thursday during a hearing in San Diego.
James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
Most of the criticism was directed at the Food and Drug Administration, which approved 21 new drugs last year, compared to 36 in 2004.
“There are whole areas (of drug development) that venture capitalists won’t pursue because the regulatory barriers are too high,” said David Gollaher, president and chief executive of the California Healthcare Institute in La Jolla.
The complaints were familiar to anyone who has followed drug and medical device development in the United States over the past several years.
Gollaher and the other experts delivered their comments to Rep. Darrell Issa, R-Vista, during a morning public forum at the University of California San Diego. Since he became chairman of the House Oversight and Government Reform Committee in early January, Issa has hosted 10 such gatherings around the country focused on regulations that stifle economic expansion.
For the latest gathering, he returned to his home county, where more than 400 companies make up a major biotechnology hub that employs more than 40,000 people, according to the San Diego trade group Biocom.
Issa was joined by Reps. Susan Davis, D-San Diego; Brian Bilbray, R-Solana Beach; and Duncan Hunter, R-Alpine.
Issa’s committee has broad investigative power, but any legislation addressing specific regulatory changes would be handled by other congressional panels that directly oversee the related agencies.
“We’re here today because San Diego is a miraculous story of biotech,” Issa said in comments that opened the 1½-hour session.
To aid his investigation, Issa solicited comments from hundreds of individuals, companies and trade groups, including many in the biotechnology and pharmaceutical industries, both directly and through a special website, americanjobcreators.com.
“We were shocked to find out that the FDA is often one of the greatest impediments to job creation,” the congressman said.
Critics of the agency say the problem is most clearly displayed in the increasing amount of time that it takes the agency to process new product applications.
Since 2007, drug review times by the FDA have increased by 28 percent, while evaluations of devices have taken as much as 75 percent more time, Gollaher said.
They also point to a recent string of unexpected new drug rejections by the agency that forced developers to perform new tests on their experimental medications.
Just in the past six months, the FDA turned down three drugs from San Diego companies: diet pills from Arena Pharmaceuticals and Orexigen Therapeutics, and a weekly injectable diabetes therapy from Amylin.
In a recent survey by Biocom, industry executives said the agency’s review process lacks transparency, often becomes sidetracked by unexpected issues and takes too much time.
“We see a growing concern that the FDA is becoming detached from the industry,” said Joe Panetta, president and chief executive of Biocom.
Many of the problems can be blamed on a cultural change at the agency that raised the emphasis on potential risks that new drugs and devices pose in the wake of a long string of high-profile medical product recalls, Gollaher said.
Still, some people say the changes have been good. Public Citizen and other consumer advocacy groups have praised the FDA for scrutinizing new medical products more intensely and requiring more safety testing before allowing them onto the market.
One possible way of shifting the agency’s focus more toward the potential benefits of new products is to give a formal role in the regulatory review process to the patients who would use the drugs and devices, said Duane Roth, chief executive of Connect San Diego, a nonprofit support group for fledgling technology companies.
“It’s their disease,” he said. “It’s not yours, and it’s not ours. Until they get in there to help us, I don’t think much will change.”
UCSD Chancellor Marye Anne Fox implored the lawmakers to resist urges to cut basic science grant funding from the National Institutes of Health, which sent $824 million to her university and other scientific institutes in the county last year.
The money produces many of the discoveries that are later taken up by biotechnology companies and turned into products.
keith.darce@uniontrib.com (619) 293-1020
Online PR News – 28-April-2011 –Harris James Associates Update: Overly cautious government regulators, threats to basic science research funding and burdensome taxes are holding back job creation by drug and medical device companies and slowing the delivery of innovative new therapies to patients, biotechnology industry experts told federal lawmakers Thursday during a hearing in San Diego.
James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
Most of the criticism was directed at the Food and Drug Administration, which approved 21 new drugs last year, compared to 36 in 2004.
“There are whole areas (of drug development) that venture capitalists won’t pursue because the regulatory barriers are too high,” said David Gollaher, president and chief executive of the California Healthcare Institute in La Jolla.
The complaints were familiar to anyone who has followed drug and medical device development in the United States over the past several years.
Gollaher and the other experts delivered their comments to Rep. Darrell Issa, R-Vista, during a morning public forum at the University of California San Diego. Since he became chairman of the House Oversight and Government Reform Committee in early January, Issa has hosted 10 such gatherings around the country focused on regulations that stifle economic expansion.
For the latest gathering, he returned to his home county, where more than 400 companies make up a major biotechnology hub that employs more than 40,000 people, according to the San Diego trade group Biocom.
Issa was joined by Reps. Susan Davis, D-San Diego; Brian Bilbray, R-Solana Beach; and Duncan Hunter, R-Alpine.
Issa’s committee has broad investigative power, but any legislation addressing specific regulatory changes would be handled by other congressional panels that directly oversee the related agencies.
“We’re here today because San Diego is a miraculous story of biotech,” Issa said in comments that opened the 1½-hour session.
To aid his investigation, Issa solicited comments from hundreds of individuals, companies and trade groups, including many in the biotechnology and pharmaceutical industries, both directly and through a special website, americanjobcreators.com.
“We were shocked to find out that the FDA is often one of the greatest impediments to job creation,” the congressman said.
Critics of the agency say the problem is most clearly displayed in the increasing amount of time that it takes the agency to process new product applications.
Since 2007, drug review times by the FDA have increased by 28 percent, while evaluations of devices have taken as much as 75 percent more time, Gollaher said.
They also point to a recent string of unexpected new drug rejections by the agency that forced developers to perform new tests on their experimental medications.
Just in the past six months, the FDA turned down three drugs from San Diego companies: diet pills from Arena Pharmaceuticals and Orexigen Therapeutics, and a weekly injectable diabetes therapy from Amylin.
In a recent survey by Biocom, industry executives said the agency’s review process lacks transparency, often becomes sidetracked by unexpected issues and takes too much time.
“We see a growing concern that the FDA is becoming detached from the industry,” said Joe Panetta, president and chief executive of Biocom.
Many of the problems can be blamed on a cultural change at the agency that raised the emphasis on potential risks that new drugs and devices pose in the wake of a long string of high-profile medical product recalls, Gollaher said.
Still, some people say the changes have been good. Public Citizen and other consumer advocacy groups have praised the FDA for scrutinizing new medical products more intensely and requiring more safety testing before allowing them onto the market.
One possible way of shifting the agency’s focus more toward the potential benefits of new products is to give a formal role in the regulatory review process to the patients who would use the drugs and devices, said Duane Roth, chief executive of Connect San Diego, a nonprofit support group for fledgling technology companies.
“It’s their disease,” he said. “It’s not yours, and it’s not ours. Until they get in there to help us, I don’t think much will change.”
UCSD Chancellor Marye Anne Fox implored the lawmakers to resist urges to cut basic science grant funding from the National Institutes of Health, which sent $824 million to her university and other scientific institutes in the county last year.
The money produces many of the discoveries that are later taken up by biotechnology companies and turned into products.
keith.darce@uniontrib.com (619) 293-1020
Harris James Associates News: Nautic Partners buys Omnicare Clinical Research
http://www.onlineprnews.com/news/133166-1304057284-harris-james-associates-news-nautic-partners-buys-omnicare-clinical-research.html
Online PR News – 30-April-2011 –By PBN Staff, PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on Thursday.
Harris James Associates News Compilation - JHA mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
Omnicare CR, headquartered in King of Prussia, Pa., conducts early phase, phase II, III and late phase clinical trials for pharmaceutical, biotechnology and medical device industries. It also provides technical services supporting clinical trials, with a focus on data management and biostatistics services.
As part of the deal, its parent company, Ominicare Inc., has provided Omnicare CR with access to its proprietary database of de-identified information exclusive to the field of clinical research and lasting for five years.
“Omnicare has carved out an attractive niche in the [clinical research organization] industry as a global, full-service provider serving the mid-sized pharmaceutical market, the medical device market and the biotechnology market,” said Chris Crosby, managing director of Nautic. The firm did not disclose the financial details of the acquisition.
It is the 10th investment by Nautic Partners’ most recent fund, Nautic Partners VI, and its third health care investment.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Online PR News – 30-April-2011 –By PBN Staff, PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on Thursday.
Harris James Associates News Compilation - JHA mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
Omnicare CR, headquartered in King of Prussia, Pa., conducts early phase, phase II, III and late phase clinical trials for pharmaceutical, biotechnology and medical device industries. It also provides technical services supporting clinical trials, with a focus on data management and biostatistics services.
As part of the deal, its parent company, Ominicare Inc., has provided Omnicare CR with access to its proprietary database of de-identified information exclusive to the field of clinical research and lasting for five years.
“Omnicare has carved out an attractive niche in the [clinical research organization] industry as a global, full-service provider serving the mid-sized pharmaceutical market, the medical device market and the biotechnology market,” said Chris Crosby, managing director of Nautic. The firm did not disclose the financial details of the acquisition.
It is the 10th investment by Nautic Partners’ most recent fund, Nautic Partners VI, and its third health care investment.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Harris James Associates News: Nautic Partners buys Omnicare Clinical Research
http://www.pressbox.co.uk/detailed/Business/Harris_James_Associates_Our_Strategy_656036.html
By PBN Staff, PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on Thursday.
Harris James Associates News Compilation - JHA mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
Omnicare CR, headquartered in King of Prussia, Pa., conducts early phase, phase II, III and late phase clinical trials for pharmaceutical, biotechnology and medical device industries. It also provides technical services supporting clinical trials, with a focus on data management and biostatistics services.
As part of the deal, its parent company, Ominicare Inc., has provided Omnicare CR with access to its proprietary database of de-identified information exclusive to the field of clinical research and lasting for five years.
“Omnicare has carved out an attractive niche in the [clinical research organization] industry as a global, full-service provider serving the mid-sized pharmaceutical market, the medical device market and the biotechnology market,” said Chris Crosby, managing director of Nautic. The firm did not disclose the financial details of the acquisition.
It is the 10th investment by Nautic Partners’ most recent fund, Nautic Partners VI, and its third health care investment.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
By PBN Staff, PROVIDENCE – Private equity firm Nautic Partners acquired Omnicare Clinical Research on Thursday.
Harris James Associates News Compilation - JHA mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
Omnicare CR, headquartered in King of Prussia, Pa., conducts early phase, phase II, III and late phase clinical trials for pharmaceutical, biotechnology and medical device industries. It also provides technical services supporting clinical trials, with a focus on data management and biostatistics services.
As part of the deal, its parent company, Ominicare Inc., has provided Omnicare CR with access to its proprietary database of de-identified information exclusive to the field of clinical research and lasting for five years.
“Omnicare has carved out an attractive niche in the [clinical research organization] industry as a global, full-service provider serving the mid-sized pharmaceutical market, the medical device market and the biotechnology market,” said Chris Crosby, managing director of Nautic. The firm did not disclose the financial details of the acquisition.
It is the 10th investment by Nautic Partners’ most recent fund, Nautic Partners VI, and its third health care investment.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Harris James Associates – Our Strategy
http://www.pressbox.co.uk/detailed/Business/Harris_James_Associates_Our_Strategy_656036.html
We believe strongly in the concept of economic and market-led research. This "top down" approach is aimed at identifying the most vibrant and promising market sectors in which to direct its considerable industry and company research capabilities. We believe in the long term growth and development of the global economy as the world's people strive for a healthier and higher standard of living, particularly in those emerging economies that account for fully half of the global population. While there are many and varied stumbling blocks on the path of global economic and social progress, Harris James Associates recognizes that there are always sectors that exhibit superior potential in the dynamics of global development. We believe that selectivity is the key to long term investment success in the stock market......
Portfolio Balancing
Rebalancing a person's investment decision profile can become a vital need due to private lifestyle adjustments for instance age, earnings, pension, inheritances, or even purchase or sale of a property or another significant property such as property, brand new assets requirements, as well as an modification in private associated risk threshold, and so on. As well, rebalancing is often required as a result of changes in asset allocation due to altered investment expectations, or to realign portfolio weightings in line with target allocations due to changing values of individual portfolio holdings. As part of the HJA commitment to excellence, and our focus on unparalleled client service, your HJA Account Executive will routinely monitor, and provide assistance when portfolio rebalancing is advised.
Timely Advice
Whether one is a seasoned investor or a newcomer to the world of private investing, your HJA representative is prepared to assist in any way practical. Advice regarding any or all aspects of your personal investment program, its overall wealth building strategy and tactical recommendations in light of changing market circumstances is yours for the asking. When Harris James Associates research discovers a compelling stock investment that meets with your overall objectives, you will be advised in a timely manner so that you may consider it for your portfolio without undue delay. Or when changing circumstances suggest a liquidation of a given investment, and because you are the ultimate decision maker, we will advise you of such changes with all practical haste.
MERGERS and ACQUISITIONS - Maximizing Your Value
Harris James Associates offers a comprehensive range of Merger and Acquisition services to help you identify strategic opportunities and develop and execute integration plans, including:
Business due diligence
Integration strategy check
Post-merger integration plan management
Harris James Associates have worked with a lot of businesses in all key industries on national and cross-border merger and acquisition projects. With our extensive consulting, technology and outsourcing expertise, clients can expect a smooth and efficient integration that yields positive results. Discover what we can do for your business.
Business due diligence
The reputation, integrity and ultimately the success of your business increasingly depends upon developing and maintaining the confidence and trust of your domestic and international clients, investors and regulators. Conducting proper due diligence is essential in eliminating fraud, managing risk and maintaining compliance with regulations.
International Due Diligence process is vital to virtually all types of
We believe strongly in the concept of economic and market-led research. This "top down" approach is aimed at identifying the most vibrant and promising market sectors in which to direct its considerable industry and company research capabilities. We believe in the long term growth and development of the global economy as the world's people strive for a healthier and higher standard of living, particularly in those emerging economies that account for fully half of the global population. While there are many and varied stumbling blocks on the path of global economic and social progress, Harris James Associates recognizes that there are always sectors that exhibit superior potential in the dynamics of global development. We believe that selectivity is the key to long term investment success in the stock market......
Portfolio Balancing
Rebalancing a person's investment decision profile can become a vital need due to private lifestyle adjustments for instance age, earnings, pension, inheritances, or even purchase or sale of a property or another significant property such as property, brand new assets requirements, as well as an modification in private associated risk threshold, and so on. As well, rebalancing is often required as a result of changes in asset allocation due to altered investment expectations, or to realign portfolio weightings in line with target allocations due to changing values of individual portfolio holdings. As part of the HJA commitment to excellence, and our focus on unparalleled client service, your HJA Account Executive will routinely monitor, and provide assistance when portfolio rebalancing is advised.
Timely Advice
Whether one is a seasoned investor or a newcomer to the world of private investing, your HJA representative is prepared to assist in any way practical. Advice regarding any or all aspects of your personal investment program, its overall wealth building strategy and tactical recommendations in light of changing market circumstances is yours for the asking. When Harris James Associates research discovers a compelling stock investment that meets with your overall objectives, you will be advised in a timely manner so that you may consider it for your portfolio without undue delay. Or when changing circumstances suggest a liquidation of a given investment, and because you are the ultimate decision maker, we will advise you of such changes with all practical haste.
MERGERS and ACQUISITIONS - Maximizing Your Value
Harris James Associates offers a comprehensive range of Merger and Acquisition services to help you identify strategic opportunities and develop and execute integration plans, including:
Business due diligence
Integration strategy check
Post-merger integration plan management
Harris James Associates have worked with a lot of businesses in all key industries on national and cross-border merger and acquisition projects. With our extensive consulting, technology and outsourcing expertise, clients can expect a smooth and efficient integration that yields positive results. Discover what we can do for your business.
Business due diligence
The reputation, integrity and ultimately the success of your business increasingly depends upon developing and maintaining the confidence and trust of your domestic and international clients, investors and regulators. Conducting proper due diligence is essential in eliminating fraud, managing risk and maintaining compliance with regulations.
International Due Diligence process is vital to virtually all types of
Harris James Associates Update: Congressional forum on biotech jobs focuses on FDA By Keith Darcé
http://www.release-news.com/index.php/finance/95748-harris-james-associates-update-congressional-forum-on-biotech-jobs-focuses-on-fda-by-keith-darce.html
Harris James Associates Update: Overly cautious government regulators, threats to basic science research funding and burdensome taxes are holding back job creation by drug and medical device companies and slowing the delivery of innovative new therapies to patients, biotechnology industry experts told federal lawmakers Thursday during a hearing in San Diego. James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. Most of the criticism was directed at the Food and Drug Administration, which approved 21 new drugs last year, compared to 36 in 2004.
"There are whole areas (of drug development) that venture capitalists won't pursue because the regulatory barriers are too high," said David Gollaher, president and chief executive of the California Healthcare Institute in La Jolla. The complaints were familiar to anyone who has followed drug and medical device development in the United States over the past several years. Gollaher and the other experts delivered their comments to Rep. Darrell Issa, R-Vista, during a morning public forum at the University of California San Diego. Since he became chairman of the House Oversight and Government Reform Committee in early January, Issa has hosted 10 such gatherings around the country focused on regulations that stifle economic expansion. For the latest gathering, he returned to his home county, where more than 400 companies make up a major biotechnology hub that employs more than 40,000 people, according to the San Diego trade group Biocom. Issa was joined by Reps.
Susan Davis, D-San Diego; Brian Bilbray, R-Solana Beach; and Duncan Hunter, R-Alpine. Issa's committee has broad investigative power, but any legislation addressing specific regulatory changes would be handled by other congressional panels that directly oversee the related agencies. "We're here today because San Diego is a miraculous story of biotech," Issa said in comments that opened the 1½-hour session. To aid his investigation, Issa solicited comments from hundreds of individuals, companies and trade groups, including many in the biotechnology and pharmaceutical industries, both directly and through a special website, americanjobcreators.com. "We were shocked to find out that the FDA is often one of the greatest impediments to job creation," the congressman said.
Critics of the agency say the problem is most clearly displayed in the increasing amount of time that it takes the agency to process new product applications. Since 2007, drug review times by the FDA have increased by 28 percent, while evaluations of devices have taken as much as 75 percent more time, Gollaher said. They also point to a recent string of unexpected new drug rejections by the agency that forced developers to perform new tests on their experimental medications. Just in the past six months, the FDA turned down three drugs from San Diego companies: diet pills from Arena Pharmaceuticals and Orexigen Therapeutics, and a weekly injectable diabetes therapy from Amylin. In a recent survey by Biocom, industry executives said the agency's review process lacks transparency, often becomes sidetracked by unexpected issues and takes too much time.
"We see a growing concern that the FDA is becoming detached from the industry," said Joe Panetta, president and chief executive of Biocom. Many of the problems can be blamed on a cultural change at the agency that raised the emphasis on potential risks that new drugs and devices pose in the wake of a long string of high-profile medical product recalls, Gollaher said. Still, some people say the changes have been good. Public Citizen and other consumer advocacy groups have praised the FDA for scrutinizing new medical products more intensely and requiring more safety testing before allowing them onto the market. One possible way of shifting the agency's focus more toward the potential benefits of new products is to give a formal role in the regulatory review process to the patients who would use the drugs and devices, said Duane Roth, chief executive of Connect San Diego, a nonprofit support group for fledgling technology companies. "It's their disease," he said.
"It's not yours, and it's not ours. Until they get in there to help us, I don't think much will change." UCSD Chancellor Marye Anne Fox implored the lawmakers to resist urges to cut basic science grant funding from the National Institutes of Health, which sent $824 million to her university and other scientific institutes in the county last year. The money produces many of the discoveries that are later taken up by biotechnology companies and turned into products. keith.darce@uniontrib.com (619) 293-1020 James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Harris James Associates Update: Overly cautious government regulators, threats to basic science research funding and burdensome taxes are holding back job creation by drug and medical device companies and slowing the delivery of innovative new therapies to patients, biotechnology industry experts told federal lawmakers Thursday during a hearing in San Diego. James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful. Most of the criticism was directed at the Food and Drug Administration, which approved 21 new drugs last year, compared to 36 in 2004.
"There are whole areas (of drug development) that venture capitalists won't pursue because the regulatory barriers are too high," said David Gollaher, president and chief executive of the California Healthcare Institute in La Jolla. The complaints were familiar to anyone who has followed drug and medical device development in the United States over the past several years. Gollaher and the other experts delivered their comments to Rep. Darrell Issa, R-Vista, during a morning public forum at the University of California San Diego. Since he became chairman of the House Oversight and Government Reform Committee in early January, Issa has hosted 10 such gatherings around the country focused on regulations that stifle economic expansion. For the latest gathering, he returned to his home county, where more than 400 companies make up a major biotechnology hub that employs more than 40,000 people, according to the San Diego trade group Biocom. Issa was joined by Reps.
Susan Davis, D-San Diego; Brian Bilbray, R-Solana Beach; and Duncan Hunter, R-Alpine. Issa's committee has broad investigative power, but any legislation addressing specific regulatory changes would be handled by other congressional panels that directly oversee the related agencies. "We're here today because San Diego is a miraculous story of biotech," Issa said in comments that opened the 1½-hour session. To aid his investigation, Issa solicited comments from hundreds of individuals, companies and trade groups, including many in the biotechnology and pharmaceutical industries, both directly and through a special website, americanjobcreators.com. "We were shocked to find out that the FDA is often one of the greatest impediments to job creation," the congressman said.
Critics of the agency say the problem is most clearly displayed in the increasing amount of time that it takes the agency to process new product applications. Since 2007, drug review times by the FDA have increased by 28 percent, while evaluations of devices have taken as much as 75 percent more time, Gollaher said. They also point to a recent string of unexpected new drug rejections by the agency that forced developers to perform new tests on their experimental medications. Just in the past six months, the FDA turned down three drugs from San Diego companies: diet pills from Arena Pharmaceuticals and Orexigen Therapeutics, and a weekly injectable diabetes therapy from Amylin. In a recent survey by Biocom, industry executives said the agency's review process lacks transparency, often becomes sidetracked by unexpected issues and takes too much time.
"We see a growing concern that the FDA is becoming detached from the industry," said Joe Panetta, president and chief executive of Biocom. Many of the problems can be blamed on a cultural change at the agency that raised the emphasis on potential risks that new drugs and devices pose in the wake of a long string of high-profile medical product recalls, Gollaher said. Still, some people say the changes have been good. Public Citizen and other consumer advocacy groups have praised the FDA for scrutinizing new medical products more intensely and requiring more safety testing before allowing them onto the market. One possible way of shifting the agency's focus more toward the potential benefits of new products is to give a formal role in the regulatory review process to the patients who would use the drugs and devices, said Duane Roth, chief executive of Connect San Diego, a nonprofit support group for fledgling technology companies. "It's their disease," he said.
"It's not yours, and it's not ours. Until they get in there to help us, I don't think much will change." UCSD Chancellor Marye Anne Fox implored the lawmakers to resist urges to cut basic science grant funding from the National Institutes of Health, which sent $824 million to her university and other scientific institutes in the county last year. The money produces many of the discoveries that are later taken up by biotechnology companies and turned into products. keith.darce@uniontrib.com (619) 293-1020 James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Harris James Associates Biomedicine News: Can Hobbyists and Hackers Transform Biotechnology?
http://www.openpr.com/news/172549/Harris-James-Associates-Biomedicine-News-Can-Hobbyists-and-Hackers-Transform-Biotechnology.html
(openPR) - James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter.
(openPR) - James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter.
For most of us, managing our health means visiting a doctor. The more serious our concerns, the more specialized a medical expert we seek. Our bodies often feel like foreign and frightening lands, and we are happy to let someone with an MD serve as our tour guide. For most of us, our own DNA never makes it onto our personal reading list.
harris james associates: Contact Us
http://www.harrisjamesassociates.com/contactus.html
80 Broad Street, New York City, New York 10004, United States
80 Broad Street, New York City, New York 10004, United States
Tel # 1 917 3381687 Fax # 1 917 5917329 Email: info@harrisjamesassociates.com
Harris James Associates Compiled News: Young Biotech Firms Seek Long Term Relevance
http://www.your-story.org/harris-james-associates-compiled-news-young-biotech-firms-seek-long-term-relevance-238750/http://www.your-story.org/harris-james-associates-compiled-news-young-biotech-firms-seek-long-term-relevance-238750/
James Harris Associates mission is to embrace our client’s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
The Bedford Report Provides Analyst Research on Vivus and Avanir Pharmaceuticals
NEW YORK, NY–(Marketwire – April 18, 2011) – There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Vivus, Inc. (NASDAQ: VVUS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:
www.bedfordreport.com/2011-04-VVUS
www.bedfordreport.com/2011-04-AVNR
IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Earlier this month shares of Vivus surged after the company released a study that may prompt US regulators to approve its weight loss drug, Qnexa. According to research presented at the American College of Cardiology meeting in New Orleans, Vivus’s once-daily pill helped people reduce dependence on blood pressure pills and decrease their triglycerides.
In October the FDA declined to approve Qnexa and asked for more study results and additional information about possible health risks, including major cardiovascular events. The FDA also has said new clinical trials might not be required to satisfy a request for more information about the drug or for it to eventually gain approval.
Also this month Avanir Pharmaceuticals filed an Investigational New Drug application with the Food and Drug Administration to begin a Phase II trial for its investigational drug, AVP-923, in the treatment of central neuropathic pain in patients with multiple sclerosis.
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
James Harris Associates mission is to embrace our client’s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
The Bedford Report Provides Analyst Research on Vivus and Avanir Pharmaceuticals
NEW YORK, NY–(Marketwire – April 18, 2011) – There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Vivus, Inc. (NASDAQ: VVUS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:
www.bedfordreport.com/2011-04-VVUS
www.bedfordreport.com/2011-04-AVNR
IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Earlier this month shares of Vivus surged after the company released a study that may prompt US regulators to approve its weight loss drug, Qnexa. According to research presented at the American College of Cardiology meeting in New Orleans, Vivus’s once-daily pill helped people reduce dependence on blood pressure pills and decrease their triglycerides.
In October the FDA declined to approve Qnexa and asked for more study results and additional information about possible health risks, including major cardiovascular events. The FDA also has said new clinical trials might not be required to satisfy a request for more information about the drug or for it to eventually gain approval.
Also this month Avanir Pharmaceuticals filed an Investigational New Drug application with the Food and Drug Administration to begin a Phase II trial for its investigational drug, AVP-923, in the treatment of central neuropathic pain in patients with multiple sclerosis.
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Harris James Associates Biomedicine News: Can Hobbyists and Hackers Transform Biotechnology?
http://www.blochure.com/harris-james-associates-biomedicine-news-can-hobbyists-and-hackers-transform-biotechnology-3573/
James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter.
For most of us, managing our health means visiting a doctor. The more serious our concerns, the more specialized a medical expert we seek. Our bodies often feel like foreign and frightening lands, and we are happy to let someone with an MD serve as our tour guide. For most of us, our own DNA never makes it onto our personal reading list.
Biohackers are on a mission to change all that. These do-it-yourself biology hobbyists want to bring biotechnology out of institutional labs and into our homes. Following in the footsteps of revolutionaries like Steve Jobs and Steve Wozniak, who built the first Apple computer in Jobs's garage, and Sergey Brin and Larry Page, who invented Google in a friend's garage, biohackers are attempting bold feats of genetic engineering, drug development, and biotech research in makeshift home laboratories.
In Biopunk, journalist Marcus Wohlsen surveys the rising tide of the biohacker movement, which has been made possible by a convergence of better and cheaper technologies. For a few hundred dollars, anyone can send some spit to a sequencing company and receive a complete DNA scan, and then use free software to analyze the results. Custom-made DNA can be mail-ordered off websites, and affordable biotech gear is available on Craigslist and eBay.
Wohlson discovers that biohackers, like the open-source programmers and software hackers who came before, are united by a profound idealism. They believe in the power of individuals as opposed to corporate interests, in the wisdom of crowds as opposed to the single-mindedness of experts, and in the incentive to do good for the world as opposed to the need to turn a profit. Suspicious of scientific elitism and inspired by the success of open-source computing, the bio DIYers believe that individuals have a fundamental right to biological information, that spreading the tools of biotech to the masses will accelerate the pace of progress, and that the fruits of the biosciences should be delivered into the hands of the people who need them the most.
With all their ingenuity and idealism, it's difficult not to root for the biohackers Wohlsen meets. Take MIT grad student Kay Aull, who built her own genetic testing kit in her closet after her father was diagnosed with the hereditary disease hemochromatosis. "Aull's test does not represent new science but a new way of doing science," Wohlsen writes. Aull's self-test for the disease-causing mutation came back positive.
Or take Meredith Patterson, who is trying to create a cheap, decentralized way to test milk for melamine poisoning without relying on government regulators. Patterson has written a "Biopunk Manifesto" that reads in part, "Scientific literacy empowers everyone who possesses it to be active contributors to their own health care, the quality of their food, water and air, their very interactions with their own bodies and the complex world around them."
Biohackers Josh Perfetto and Tito Jankowski created OpenPCR, a cheap, hackable DNA Xerox machine (PCR stands for "polymerase chain reaction," the name for a method of replicating DNA). Interested biohackers can pre-order one for just over $500 or, once it's ready, download the blueprint free and make their own. According to the website, its apps include DNA sequencing and a test to "check that sushi is legit." Jankowski "hopes to introduce young people to the tools and techniques of biotech in a way that makes gene tweaking as much a part of everyday technology as texting," Wohlsen writes. Jankowski, together with Joseph Jackson and Eri Gentry, also founded BioCurious, a collaborative lab space for biohackers in the Bay area. "Got an idea for a startup? Join the DIY, 'garage biology' movement and found a new breed of biotech," their website exhorts.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
James Harris Associates mission is to embrace our client's goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
DIY Scientists Hack the Software of Life, Marcus Wohlsen explores the new movement in garage-based biotech. By Amanda Gefter.
For most of us, managing our health means visiting a doctor. The more serious our concerns, the more specialized a medical expert we seek. Our bodies often feel like foreign and frightening lands, and we are happy to let someone with an MD serve as our tour guide. For most of us, our own DNA never makes it onto our personal reading list.
Biohackers are on a mission to change all that. These do-it-yourself biology hobbyists want to bring biotechnology out of institutional labs and into our homes. Following in the footsteps of revolutionaries like Steve Jobs and Steve Wozniak, who built the first Apple computer in Jobs's garage, and Sergey Brin and Larry Page, who invented Google in a friend's garage, biohackers are attempting bold feats of genetic engineering, drug development, and biotech research in makeshift home laboratories.
In Biopunk, journalist Marcus Wohlsen surveys the rising tide of the biohacker movement, which has been made possible by a convergence of better and cheaper technologies. For a few hundred dollars, anyone can send some spit to a sequencing company and receive a complete DNA scan, and then use free software to analyze the results. Custom-made DNA can be mail-ordered off websites, and affordable biotech gear is available on Craigslist and eBay.
Wohlson discovers that biohackers, like the open-source programmers and software hackers who came before, are united by a profound idealism. They believe in the power of individuals as opposed to corporate interests, in the wisdom of crowds as opposed to the single-mindedness of experts, and in the incentive to do good for the world as opposed to the need to turn a profit. Suspicious of scientific elitism and inspired by the success of open-source computing, the bio DIYers believe that individuals have a fundamental right to biological information, that spreading the tools of biotech to the masses will accelerate the pace of progress, and that the fruits of the biosciences should be delivered into the hands of the people who need them the most.
With all their ingenuity and idealism, it's difficult not to root for the biohackers Wohlsen meets. Take MIT grad student Kay Aull, who built her own genetic testing kit in her closet after her father was diagnosed with the hereditary disease hemochromatosis. "Aull's test does not represent new science but a new way of doing science," Wohlsen writes. Aull's self-test for the disease-causing mutation came back positive.
Or take Meredith Patterson, who is trying to create a cheap, decentralized way to test milk for melamine poisoning without relying on government regulators. Patterson has written a "Biopunk Manifesto" that reads in part, "Scientific literacy empowers everyone who possesses it to be active contributors to their own health care, the quality of their food, water and air, their very interactions with their own bodies and the complex world around them."
Biohackers Josh Perfetto and Tito Jankowski created OpenPCR, a cheap, hackable DNA Xerox machine (PCR stands for "polymerase chain reaction," the name for a method of replicating DNA). Interested biohackers can pre-order one for just over $500 or, once it's ready, download the blueprint free and make their own. According to the website, its apps include DNA sequencing and a test to "check that sushi is legit." Jankowski "hopes to introduce young people to the tools and techniques of biotech in a way that makes gene tweaking as much a part of everyday technology as texting," Wohlsen writes. Jankowski, together with Joseph Jackson and Eri Gentry, also founded BioCurious, a collaborative lab space for biohackers in the Bay area. "Got an idea for a startup? Join the DIY, 'garage biology' movement and found a new breed of biotech," their website exhorts.
James Harris Associates is devoted to providing operational, technological, and regulatory services to the Pharmaceutical and Biotechnology industries. Our confidential services are provided in manufacturing, quality, engineering, materials management and logistics, regulatory, and training. We routinely serve clients in the United States, Europe and Asia. Skilled consultants assist in facility or process upgradesm validation, start-up, new facility design, location services, FDA liaison, and product registration.
Cricket: Glamorgan’s James Harris eyes England honours
http://harrisidurreyoung.blogspot.com/2011/04/cricket-glamorgans-james-harris-eyes.html?spref=tw
too much for Harris to win his first cap on home soil next month – Cardiff’s Swalec Stadium hosts England’s first Test against Sri Lanka – but the all-rounder isn’t giving up on a Three Lions debut this year.
Some of Glamorgan’s biggest names, including Gilbert Parkhouse, Peter Walker, Jeff Jones and teammate Robert Croft have represented England at Test match level and Harris is desperate to make the step up.
He believes touring with the England Lions, formerly England A, this winter gave him the perfect grounding for a call-up to the first team.
Pontarddulais-born Harris, still only 20, was in the runs and among the wickets on the Lions’ nine-match tour of the West Indies.
While Harris has already written his name into the Glamorgan record books for his feats as a fresh-faced teenager, he is now ready to push for full international honours.
His immediate focus is on getting Glamorgan’s championship season off to a winning start as they attempt to put the frustration of last year and the turbulent events off the field during the winter behind them.
For Harris, the early part of the off-season was spent at the National Cricket Performance Centre in Loughborough, ironing out the creases in his game before travelling to the Caribbean in January.
too much for Harris to win his first cap on home soil next month – Cardiff’s Swalec Stadium hosts England’s first Test against Sri Lanka – but the all-rounder isn’t giving up on a Three Lions debut this year.
Some of Glamorgan’s biggest names, including Gilbert Parkhouse, Peter Walker, Jeff Jones and teammate Robert Croft have represented England at Test match level and Harris is desperate to make the step up.
He believes touring with the England Lions, formerly England A, this winter gave him the perfect grounding for a call-up to the first team.
While Harris has already written his name into the Glamorgan record books for his feats as a fresh-faced teenager, he is now ready to push for full international honours.
His immediate focus is on getting Glamorgan’s championship season off to a winning start as they attempt to put the frustration of last year and the turbulent events off the field during the winter behind them.
For Harris, the early part of the off-season was spent at the National Cricket Performance Centre in Loughborough, ironing out the creases in his game before travelling to the Caribbean in January.
Monday, April 25, 2011
Harris James Associates Socially Accountable Investing
http://www.blochure.com/harris-james-associates-socially-accountable-investing-3330/
Do excellent whilst earning profits: A guidebook to socially accountable investing
What is socially accountable investing?
Socially accountable investing (SRI) describes an investment strategy that brings together the intentions to increase both equally fiscal return and social excellent. Generally, socially responsible traders favor company practices that happen to be environmentally accountable, help workplace diversity and grow products security and excellent.
Harris James Associates New York, ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client's success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
RI tactics supply investors using the opportunity to produce beneficial modify on the planet by their personal decisions whilst remaining concentrated on their long-term investment strategy.
Investing funds in a socially aware method has gained reputation given that the 1970s, while the origins of your idea is often traced again for the 17th century. The idea grew for any number of good reasons, including concerns with regards to the setting, purchaser and employee rights, and army actions.
Lots of individuals who had been civil rights and anti-war protestors in the 1960s grew to become traders inside 1970s and 1980s and had been searching for a way to express their convictions via their investment portfolios. The 1st mutual fund to display investments dependant on social criteria was established in 1971.
Right now, greater than 200 mutual money give investors a way to entry a social investment system. Some money are broad in nature, even though other individuals focus on a distinct bring about.
According to your Social Investment Forum, in 2007, just about one from each and every 9 dollars below qualified management within the U.s. (in excess of $2.71 trillion) was associated with socially accountable investing, outpacing the overall marketplace. Curiosity within this investment method has grown greatly given that the mid-1990s.
Alongside money and other professionally managed portfolios that specialize in socially accountable types, the Social Investment Forum studies that mainstream funds managers are also incorporating social and environmental screens into their investment choice processes. The strategy has also taken on world wide dimensions, as far more investors throughout the entire world find to promote specific leads to by way of their investment dollars.
Final results might be favorable
An indication from the aggressive performance of SRI funds will be the functionality of SRI indexes. The longest-running SRI index, the Domini 400, was started in 1990 and continues to carry out competitively. When benchmarking this index versus the S&P 500, the Domini 400 showed a 10.83% return vs. 10.33% total returns using the S&P 500.
Implementing social awareness in different ways
How can socially accountable investing be applied? This is something that can transform from investor to investor, dependant upon each individual’s views. Generally, there are three ways that investors can try to effect alter by way of their investment decisions:
• Social screening. Eliminating companies from consideration for inclusion within a portfolio as a consequence of particular practices or styles of business it pursues. Several social investors avoid companies whose products and solutions and business practices are harmful to people today, communities or the environment.
• Shareholder activism. In some cases, traders or groups of traders (this can involve mutual fund managers) will try to influence the behavior of a firm or selections by its board of directors. When this often is centered on improving financial overall performance, activism may also be a strategy to adjust a company’s business practices that might be considered detrimental to society.
This can involve filing shareholder resolutions on topics like as company governance, political contributions, gender/racial discrimination, pollution and problem labor practices, among other problems.
• Community investing. Institutions use investor capital to finance or guarantee loans to individuals or organizations to improve their own communities. Community investing projects are small and local and normally target on affordable housing, small business startups, improving community facilities and empowering minorities.
Mutual funds vs. individual investing
For most traders, mutual money offer an easy approach to gain entry towards the world of individual investing. Traders have a huge array of options available and the ability to select funds to invest in large-cap, mid-cap and small-cap stocks, and even in bond funds with a socially aware angle.
Those who invest in individual securities or use a professionally managed account have the ability to get a lot more selective in screening investments. This tactic may be most appropriate for investors whose screening criteria are extra unique than would occur with a mutual fund.
Themes arise with the times
Major social problems can usually drive the interests of investors in terms in the social screens they favor. Inside 1970s and 1980s, there was a terrific deal of pressure on investment managers to avoid investments in companies doing business in South Africa, at a time when the country maintained a policy of apartheid. From the 1990s, tobacco companies took center stage. Tobacco currently represents the most popular social display employed in socially accountable mutual funds.
Currently, there is increasing focus on the setting, as worldwide warming has turn out to be a headline issue. Consumers have taken a larger curiosity in environmentally friendly goods like hybrid cars and energy-efficient lightbulbs.
That same interest extends to investing, as far more people seek out “green” money. These portfolios could screen stocks of companies with poor pollution records and might look for to invest in technologies like as solar and wind power development.
Do excellent whilst earning profits: A guidebook to socially accountable investing
What is socially accountable investing?
Socially accountable investing (SRI) describes an investment strategy that brings together the intentions to increase both equally fiscal return and social excellent. Generally, socially responsible traders favor company practices that happen to be environmentally accountable, help workplace diversity and grow products security and excellent.
Harris James Associates New York, ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client's success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
RI tactics supply investors using the opportunity to produce beneficial modify on the planet by their personal decisions whilst remaining concentrated on their long-term investment strategy.
Investing funds in a socially aware method has gained reputation given that the 1970s, while the origins of your idea is often traced again for the 17th century. The idea grew for any number of good reasons, including concerns with regards to the setting, purchaser and employee rights, and army actions.
Lots of individuals who had been civil rights and anti-war protestors in the 1960s grew to become traders inside 1970s and 1980s and had been searching for a way to express their convictions via their investment portfolios. The 1st mutual fund to display investments dependant on social criteria was established in 1971.
Right now, greater than 200 mutual money give investors a way to entry a social investment system. Some money are broad in nature, even though other individuals focus on a distinct bring about.
According to your Social Investment Forum, in 2007, just about one from each and every 9 dollars below qualified management within the U.s. (in excess of $2.71 trillion) was associated with socially accountable investing, outpacing the overall marketplace. Curiosity within this investment method has grown greatly given that the mid-1990s.
Alongside money and other professionally managed portfolios that specialize in socially accountable types, the Social Investment Forum studies that mainstream funds managers are also incorporating social and environmental screens into their investment choice processes. The strategy has also taken on world wide dimensions, as far more investors throughout the entire world find to promote specific leads to by way of their investment dollars.
Final results might be favorable
An indication from the aggressive performance of SRI funds will be the functionality of SRI indexes. The longest-running SRI index, the Domini 400, was started in 1990 and continues to carry out competitively. When benchmarking this index versus the S&P 500, the Domini 400 showed a 10.83% return vs. 10.33% total returns using the S&P 500.
Implementing social awareness in different ways
How can socially accountable investing be applied? This is something that can transform from investor to investor, dependant upon each individual’s views. Generally, there are three ways that investors can try to effect alter by way of their investment decisions:
• Social screening. Eliminating companies from consideration for inclusion within a portfolio as a consequence of particular practices or styles of business it pursues. Several social investors avoid companies whose products and solutions and business practices are harmful to people today, communities or the environment.
• Shareholder activism. In some cases, traders or groups of traders (this can involve mutual fund managers) will try to influence the behavior of a firm or selections by its board of directors. When this often is centered on improving financial overall performance, activism may also be a strategy to adjust a company’s business practices that might be considered detrimental to society.
This can involve filing shareholder resolutions on topics like as company governance, political contributions, gender/racial discrimination, pollution and problem labor practices, among other problems.
• Community investing. Institutions use investor capital to finance or guarantee loans to individuals or organizations to improve their own communities. Community investing projects are small and local and normally target on affordable housing, small business startups, improving community facilities and empowering minorities.
Mutual funds vs. individual investing
For most traders, mutual money offer an easy approach to gain entry towards the world of individual investing. Traders have a huge array of options available and the ability to select funds to invest in large-cap, mid-cap and small-cap stocks, and even in bond funds with a socially aware angle.
Those who invest in individual securities or use a professionally managed account have the ability to get a lot more selective in screening investments. This tactic may be most appropriate for investors whose screening criteria are extra unique than would occur with a mutual fund.
Themes arise with the times
Major social problems can usually drive the interests of investors in terms in the social screens they favor. Inside 1970s and 1980s, there was a terrific deal of pressure on investment managers to avoid investments in companies doing business in South Africa, at a time when the country maintained a policy of apartheid. From the 1990s, tobacco companies took center stage. Tobacco currently represents the most popular social display employed in socially accountable mutual funds.
Currently, there is increasing focus on the setting, as worldwide warming has turn out to be a headline issue. Consumers have taken a larger curiosity in environmentally friendly goods like hybrid cars and energy-efficient lightbulbs.
That same interest extends to investing, as far more people seek out “green” money. These portfolios could screen stocks of companies with poor pollution records and might look for to invest in technologies like as solar and wind power development.
HARRIS A. JAMES, JR. ATTORNEY AT LAW
http://www.jahlawyer.com/
Personal Injury; and Insurance Related Personal Injury Litigation (Litigation Based on Insurance Company Unfair Claims Settlement Practices and Insurance Bad Faith Dealing with Injured Persons) Practice Areas:
1974, Kentucky; 1978, California; 1979, U.S. Supreme Court Admitted:
Paducah City Schools (Clark, Brazelton, Tilghman) Schools:
Duke University, B.A., 1971 College:
University of Kentucky, J.D., 1974; Selected/Elected Member Order of the Coif; Lead Articles Editor, Kentucky Law Journal, 1973-1974 Law School:
McCracken County, Kentucky and American Bar Associations; State Bar of California Member:
United States Marine Corp, 1974-1978 Military:
Paducah Rotary Club. Member, Past President and Board of Directors, Paul Harris Fellow Civic:
Highest Rating (AV) Martindale-
Hubbell:
906673148 I
Hubbell:
James Harris: harris james associates new york
http://www.pro-football-reference.com/players/H/HarrJa01.htm
James Larnell Harris
Position: QB
Height: 6-4 Weight: 210 lbs.
Born: July 20, 1947 in Monroe, LA
College: Grambling State
Drafted by the Buffalo Bills in the 8th round (192nd overall) of the 1969 NFL Draft.
Weighted Career AV (100-95-...): 38 (2322nd overall since 1950)
1-time Pro Bowler (fine print)
James Larnell Harris
Position: QB
Height: 6-4 Weight: 210 lbs.
Born: July 20, 1947 in Monroe, LA
College: Grambling State
Drafted by the Buffalo Bills in the 8th round (192nd overall) of the 1969 NFL Draft.
Weighted Career AV (100-95-...): 38 (2322nd overall since 1950)
1-time Pro Bowler (fine print)
Jim Harris (politician): harris james associates new york
http://en.wikipedia.org/wiki/Jim_Harris_%28politician%29
Harris was born in Toronto, attended Lakefield College School, and received a Bachelor of Arts degree in English and History from Queen's University in Kingston in the 1980s.[1] Initially a Progressive Conservative,[2] he was converted to green politics in 1985 after reading Green Politics by Fritjof Capra and Charlene Spretnak, which highlights the rise of the German Greens. Harris worked as the national press officer of the British Green Party in 1987.[3]
Harris was born in Toronto, attended Lakefield College School, and received a Bachelor of Arts degree in English and History from Queen's University in Kingston in the 1980s.[1] Initially a Progressive Conservative,[2] he was converted to green politics in 1985 after reading Green Politics by Fritjof Capra and Charlene Spretnak, which highlights the rise of the German Greens. Harris worked as the national press officer of the British Green Party in 1987.[3]
Biographical Snapshots of Famous Women and Minority Chemists: Snapshot- harris james associates new york
http://jchemed.chem.wisc.edu/JCEWWW/features/echemists/Bios/Harris.html
This short biographical "snapshot" provides basic information about the person's chemical work, gender, ethnicity, and cultural background. A list of references is given along with additional WWW sites to further your exploration into the life and work of this chemist.
This short biographical "snapshot" provides basic information about the person's chemical work, gender, ethnicity, and cultural background. A list of references is given along with additional WWW sites to further your exploration into the life and work of this chemist.
| James A. Harris | ||||
| ||||
| James Andrew Harris, the first African American to participate in a major new-element identification program and co-discoverer of elements 104 and 105, was born on March 26, 1932 in Waco, Texas. As a result of his parents' divorce, he moved to the San Francisco Bay Area and graduated from McClymond High School in Oakland. After earning a B.S. in chemistry at Houston-Tillotson College in Austin, Texas, Harris served in the army. Later, he joined Tracerlab, Inc. in Richmond, California, where he worked as a chemist for five years. In 1960, Harris left Tracerlab to accept a position in the Nuclear Chemistry Division of the Lawrence Radiation Laboratory at the University of California, Berkeley. He became part of the team that discovered and identified elements 104 and 105 in 1969-1970. His job was to create the targets used in the identification of elements 104 and 105. In a press release at the time, his colleague Albert Ghiorso stated that James Harris created "the best target that has ever been available for heavy-element research". In a 1973 interview with Harris, Jack Slater from Ebony magazine wrote: If Harris were to write the book [on his job-hunting experiences and the problems a black scientist encounters], it might include the half-dozen or so shocked expressions of prospective employers when he first walked into their offices. It might also include the half-dozen secretaries who refused to believe he was applying for job as a chemist rather than a janitor. "At one point," he recalls, chuckling now at an old wound. "I was even given a job test simple enough for elementary school kids--basic addition and subtraction...I told the secretary I didn't need a job that badly." (p 148)In 1973, Harris received an honorary Ph.D. from Houston-Tillotson College and later the Scientific Merit Award from the Mayor of Richmond, California. Also honored by the National Urban League with a Merit Award, he has been invited to lecture at numerous colleges and universities. In addition to a busy professional life, Harris and his wife Helen have five children. |
harris james associates new york usa
http://ezinemark.com/a/harris-james-associates-new-york-usa/
Harris James Associates Socially Accountable Investing
By: Harris James|2011-04-13|Investing
Do excellent whilst earning profits: A guidebook to socially accountable investing What is socially accountable investing? Socially accountable investing (SRI) describes an investment strategy that brings together the intentions to increase both equally fiscal return and social excellent. Central Georgia's Knowledgable and Experienced Law Firm: harris james associates new york
Harris & James, LLP is a law firm in Macon, Georgia, specializing in Eminent Domain, Estate Planning, Taxation, Business Law, Real Estate Law, Elder Law, and Franchise Law. Our firm has over 175 combined years of legal experience.
Attorneys at Law
(478) 745-9661
Attorneys at Law(478) 745-9661
Website Under Construction
Harris James Associates Socially Accountable Investing
http://www.blochure.com/harris-james-associates-socially-accountable-investing-3330/
What is socially accountable investing?
Socially accountable investing (SRI) describes an investment strategy that brings together the intentions to increase both equally fiscal return and social excellent. Generally, socially responsible traders favor company practices that happen to be environmentally accountable, help workplace diversity and grow products security and excellent.
Harris James Associates New York, ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client's success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
RI tactics supply investors using the opportunity to produce beneficial modify on the planet by their personal decisions whilst remaining concentrated on their long-term investment strategy.
What is socially accountable investing?
Socially accountable investing (SRI) describes an investment strategy that brings together the intentions to increase both equally fiscal return and social excellent. Generally, socially responsible traders favor company practices that happen to be environmentally accountable, help workplace diversity and grow products security and excellent.
Harris James Associates New York, ensures that our clients possess the best info on which to base intelligent business and financial decisions in pursuit of superior investment performance. In order to achieve and maintain that standard of information and timely advice, management and staff are committed to a level of excellence in research, market intelligence, trade executions, and client service that is both demanding and rewarding. We judge our success in maintaining that high level of excellence by the one true measurement; the satisfaction and investment performance of our growing clientele. At Harris James Associates, the Client's success is our primary objective. Investment success in these volatile times can be fleeting for many, which is why our commitment to excellence in everything we do will be a constant regardless of the often turbulent world around us.
RI tactics supply investors using the opportunity to produce beneficial modify on the planet by their personal decisions whilst remaining concentrated on their long-term investment strategy.
Harris James Associates – Our Strategy
http://www.pressbox.co.uk/detailed/Business/Harris_James_Associates_Our_Strategy_656036.html
We believe strongly in the concept of economic and market-led research. This "top down" approach is aimed at identifying the most vibrant and promising market sectors in which to direct its considerable industry and company research capabilities. We believe in the long term growth and development of the global economy as the world's people strive for a healthier and higher standard of living, particularly in those emerging economies that account for fully half of the global population. While there are many and varied stumbling blocks on the path of global economic and social progress, Harris James Associates recognizes that there are always sectors that exhibit superior potential in the dynamics of global development. We believe that selectivity is the key to long term investment success in the stock market......
Portfolio Balancing
Rebalancing a person's investment decision profile can become a vital need due to private lifestyle adjustments for instance age, earnings, pension, inheritances, or even purchase or sale of a property or another significant property such as property, brand new assets requirements, as well as an modification in private associated risk threshold, and so on. As well, rebalancing is often required as a result of changes in asset allocation due to altered investment expectations, or to realign portfolio weightings in line with target allocations due to changing values of individual portfolio holdings. As part of the HJA commitment to excellence, and our focus on unparalleled client service, your HJA Account Executive will routinely monitor, and provide assistance when portfolio rebalancing is advised.
Timely Advice
Whether one is a seasoned investor or a newcomer to the world of private investing, your HJA representative is prepared to assist in any way practical. Advice regarding any or all aspects of your personal investment program, its overall wealth building strategy and tactical recommendations in light of changing market circumstances is yours for the asking. When Harris James Associates research discovers a compelling stock investment that meets with your overall objectives, you will be advised in a timely manner so that you may consider it for your portfolio without undue delay. Or when changing circumstances suggest a liquidation of a given investment, and because you are the ultimate decision maker, we will advise you of such changes with all practical haste.
MERGERS and ACQUISITIONS - Maximizing Your Value
Harris James Associates offers a comprehensive range of Merger and Acquisition services to help you identify strategic opportunities and develop and execute integration plans, including:
Business due diligence
Integration strategy check
Post-merger integration plan management
Harris James Associates have worked with a lot of businesses in all key industries on national and cross-border merger and acquisition projects. With our extensive consulting, technology and outsourcing expertise, clients can expect a smooth and efficient integration that yields positive results. Discover what we can do for your business.
Business due diligence
The reputation, integrity and ultimately the success of your business increasingly depends upon developing and maintaining the confidence and trust of your domestic and international clients, investors and regulators. Conducting proper due diligence is essential in eliminating fraud, managing risk and maintaining compliance with regulations.
International Due Diligence process is vital to virtually all types of engagement including:
* Sales Agents or Consultants
* Joint Ventures
* Strategic Partners
* Mergers & Acquisitions
* Risk Assessment
* Distributors
* Senior Level Personnel Decisions
* Vendor Verification
* Customer Acquisition
* Conflict of Interest Investigations
Post-merger Integration
Harris James Associates has supported hundreds of post-merger integration projects.
HJA consultants draw on functional and business process expertise to manage each major milestone, from the initial merger announcement to the operational launch of the combined entity.
Our core strengths include strategic advice during the pre-deal phase, growth strategy reviews, target evaluations, strategic due diligence and post-merger integration planning and implementation.
The acquisition and integration of another business requires top management to rethink the organization’s strategic vision. Integration involves re-shaping the organization to achieve this new vision and realize merger synergies.
We believe strongly in the concept of economic and market-led research. This "top down" approach is aimed at identifying the most vibrant and promising market sectors in which to direct its considerable industry and company research capabilities. We believe in the long term growth and development of the global economy as the world's people strive for a healthier and higher standard of living, particularly in those emerging economies that account for fully half of the global population. While there are many and varied stumbling blocks on the path of global economic and social progress, Harris James Associates recognizes that there are always sectors that exhibit superior potential in the dynamics of global development. We believe that selectivity is the key to long term investment success in the stock market......
Portfolio Balancing
Rebalancing a person's investment decision profile can become a vital need due to private lifestyle adjustments for instance age, earnings, pension, inheritances, or even purchase or sale of a property or another significant property such as property, brand new assets requirements, as well as an modification in private associated risk threshold, and so on. As well, rebalancing is often required as a result of changes in asset allocation due to altered investment expectations, or to realign portfolio weightings in line with target allocations due to changing values of individual portfolio holdings. As part of the HJA commitment to excellence, and our focus on unparalleled client service, your HJA Account Executive will routinely monitor, and provide assistance when portfolio rebalancing is advised.
Timely Advice
Whether one is a seasoned investor or a newcomer to the world of private investing, your HJA representative is prepared to assist in any way practical. Advice regarding any or all aspects of your personal investment program, its overall wealth building strategy and tactical recommendations in light of changing market circumstances is yours for the asking. When Harris James Associates research discovers a compelling stock investment that meets with your overall objectives, you will be advised in a timely manner so that you may consider it for your portfolio without undue delay. Or when changing circumstances suggest a liquidation of a given investment, and because you are the ultimate decision maker, we will advise you of such changes with all practical haste.
MERGERS and ACQUISITIONS - Maximizing Your Value
Harris James Associates offers a comprehensive range of Merger and Acquisition services to help you identify strategic opportunities and develop and execute integration plans, including:
Business due diligence
Integration strategy check
Post-merger integration plan management
Harris James Associates have worked with a lot of businesses in all key industries on national and cross-border merger and acquisition projects. With our extensive consulting, technology and outsourcing expertise, clients can expect a smooth and efficient integration that yields positive results. Discover what we can do for your business.
Business due diligence
The reputation, integrity and ultimately the success of your business increasingly depends upon developing and maintaining the confidence and trust of your domestic and international clients, investors and regulators. Conducting proper due diligence is essential in eliminating fraud, managing risk and maintaining compliance with regulations.
International Due Diligence process is vital to virtually all types of engagement including:
* Sales Agents or Consultants
* Joint Ventures
* Strategic Partners
* Mergers & Acquisitions
* Risk Assessment
* Distributors
* Senior Level Personnel Decisions
* Vendor Verification
* Customer Acquisition
* Conflict of Interest Investigations
Post-merger Integration
Harris James Associates has supported hundreds of post-merger integration projects.
HJA consultants draw on functional and business process expertise to manage each major milestone, from the initial merger announcement to the operational launch of the combined entity.
Our core strengths include strategic advice during the pre-deal phase, growth strategy reviews, target evaluations, strategic due diligence and post-merger integration planning and implementation.
The acquisition and integration of another business requires top management to rethink the organization’s strategic vision. Integration involves re-shaping the organization to achieve this new vision and realize merger synergies.
Harris James Associates Compiled News: Young Biotech Firms Seek Long Term Relevance
http://www.your-story.org/harris-james-associates-compiled-news-young-biotech-firms-seek-long-term-relevance-238750/http://www.your-story.org/harris-james-associates-compiled-news-young-biotech-firms-seek-long-term-relevance-238750/
James Harris Associates mission is to embrace our client’s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
The Bedford Report Provides Analyst Research on Vivus and Avanir Pharmaceuticals
NEW YORK, NY–(Marketwire – April 18, 2011) – There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Vivus, Inc. (NASDAQ: VVUS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:
www.bedfordreport.com/2011-04-VVUS
www.bedfordreport.com/2011-04-AVNR
IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Earlier this month shares of Vivus surged after the company released a study that may prompt US regulators to approve its weight loss drug, Qnexa. According to research presented at the American College of Cardiology meeting in New Orleans, Vivus’s once-daily pill helped people reduce dependence on blood pressure pills and decrease their triglycerides.
In October the FDA declined to approve Qnexa and asked for more study results and additional information about possible health risks, including major cardiovascular events. The FDA also has said new clinical trials might not be required to satisfy a request for more information about the drug or for it to eventually gain approval.
Also this month Avanir Pharmaceuticals filed an Investigational New Drug application with the Food and Drug Administration to begin a Phase II trial for its investigational drug, AVP-923, in the treatment of central neuropathic pain in patients with multiple sclerosis.
James Harris Associates mission is to embrace our client’s goals as our own and to work as an extension of the client organization to reach our common objective. We know that we will be successful only if we make our clients more successful.
The Bedford Report Provides Analyst Research on Vivus and Avanir Pharmaceuticals
NEW YORK, NY–(Marketwire – April 18, 2011) – There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Vivus, Inc. (NASDAQ: VVUS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:
www.bedfordreport.com/2011-04-VVUS
www.bedfordreport.com/2011-04-AVNR
IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Earlier this month shares of Vivus surged after the company released a study that may prompt US regulators to approve its weight loss drug, Qnexa. According to research presented at the American College of Cardiology meeting in New Orleans, Vivus’s once-daily pill helped people reduce dependence on blood pressure pills and decrease their triglycerides.
In October the FDA declined to approve Qnexa and asked for more study results and additional information about possible health risks, including major cardiovascular events. The FDA also has said new clinical trials might not be required to satisfy a request for more information about the drug or for it to eventually gain approval.
Also this month Avanir Pharmaceuticals filed an Investigational New Drug application with the Food and Drug Administration to begin a Phase II trial for its investigational drug, AVP-923, in the treatment of central neuropathic pain in patients with multiple sclerosis.
Subscribe to:
Comments (Atom)